memantine Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
adamantane derivatives 1679 19982-08-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • memantine
  • alzantin
  • memantina
  • memantine hydrochloride
  • ebixa
  • namenda
  • maruxa
  • memantine HCl
  • nemdatine
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
  • Molecular weight: 179.31
  • Formula: C12H21N
  • CLOGP: 3.03
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -3.60
  • ROTB: 0

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2003 FDA FOREST LABS LLC

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Confusional state 891.95 37.34 313 3978 48521 4586180
Fall 762.73 37.34 317 3974 77729 4556972
Agitation 654.22 37.34 209 4082 23991 4610710
Aggression 479.80 37.34 145 4146 13754 4620947
Somnolence 463.66 37.34 189 4102 43471 4591230
Seizure 382.74 37.34 172 4119 50065 4584636
Condition aggravated 340.39 37.34 166 4125 58005 4576696
Abnormal behaviour 332.41 37.34 106 4185 11950 4622751
Hallucination 326.82 37.34 115 4176 17553 4617148
Loss of consciousness 302.97 37.34 132 4159 35550 4599151
Dizziness 296.91 37.34 182 4109 99689 4535012
Asthenia 292.29 37.34 171 4120 85992 4548709
Gait disturbance 289.90 37.34 129 4162 36511 4598190
Myoclonus 248.33 37.34 70 4221 5154 4629547
Delirium 243.25 37.34 85 4206 12667 4622034
Dementia Alzheimer's type 221.69 37.34 50 4241 1475 4633226
Bradycardia 206.01 37.34 88 4203 22481 4612220
Decreased appetite 204.16 37.34 117 4174 56280 4578421
Hallucination, visual 196.42 37.34 60 4231 5842 4628859
Urinary tract infection 192.00 37.34 102 4189 42288 4592413
Drug interaction 181.96 37.34 114 4177 64394 4570307
Syncope 175.99 37.34 89 4202 33306 4601395
Dementia 173.68 37.34 53 4238 5139 4629562
General physical health deterioration 167.29 37.34 82 4209 28696 4606005
Cognitive disorder 162.62 37.34 60 4231 10421 4624280
Dehydration 156.24 37.34 89 4202 42201 4592500
Disorientation 145.52 37.34 58 4233 12401 4622300
Hyponatraemia 139.30 37.34 69 4222 24661 4610040
Speech disorder 135.63 37.34 54 4237 11508 4623193
Product administration interrupted 134.88 37.34 21 4270 66 4634635
Epilepsy 131.27 37.34 50 4241 9468 4625233
Tremor 130.34 37.34 75 4216 36184 4598517
Lethargy 127.37 37.34 58 4233 17183 4617518
Mental status changes 125.28 37.34 52 4239 12324 4622377
Psychomotor hyperactivity 124.20 37.34 39 4252 4150 4630551
Vomiting 123.11 37.34 116 4175 119583 4515118
Depressed level of consciousness 121.54 37.34 54 4237 15100 4619601
Inappropriate antidiuretic hormone secretion 121.33 37.34 39 4252 4475 4630226
Restlessness 120.79 37.34 47 4244 9422 4625279
Pulmonary embolism 120.50 37.34 70 4221 34356 4600345
Cerebral atrophy 120.16 37.34 31 4260 1622 4633079
Blood glucose increased 120.10 37.34 62 4229 24142 4610559
Accidental overdose 118.28 37.34 46 4245 9209 4625492
Electrocardiogram QT prolonged 117.86 37.34 53 4238 15242 4619459
Medication error 114.42 37.34 51 4240 14365 4620336
Generalised tonic-clonic seizure 110.89 37.34 45 4246 10065 4624636
Malaise 109.50 37.34 96 4195 90061 4544640
Altered state of consciousness 103.20 37.34 40 4251 7931 4626770
Urinary incontinence 102.57 37.34 39 4252 7341 4627360
Balance disorder 102.42 37.34 49 4242 16207 4618494
Sedation 100.88 37.34 39 4252 7678 4627023
Hypotension 100.85 37.34 81 4210 67319 4567382
Off label use 94.13 37.34 104 4187 129009 4505692
Dyskinesia 93.93 37.34 39 4252 9236 4625465
Disturbance in attention 92.24 37.34 40 4251 10541 4624160
Weight decreased 91.25 37.34 70 4221 54394 4580307
Encephalopathy 91.15 37.34 39 4252 9948 4624753
Pancreatitis acute 89.75 37.34 37 4254 8606 4626095
Nausea 88.75 37.34 118 4173 177215 4457486
Coma 87.21 37.34 45 4246 17474 4617227
International normalised ratio increased 85.61 37.34 44 4247 16944 4617757
Fatigue 79.18 37.34 101 4190 145465 4489236
Gait inability 79.18 37.34 35 4256 9650 4625051
Anxiety 78.84 37.34 61 4230 47950 4586751
Suicidal ideation 78.40 37.34 45 4246 21538 4613163
Pneumonia 76.88 37.34 84 4207 102731 4531970
Urinary retention 75.42 37.34 34 4257 9813 4624888
Sinus bradycardia 75.22 37.34 27 4264 4322 4630379
Product use issue 74.76 37.34 46 4245 24990 4609711
Constipation 74.57 37.34 56 4235 42098 4592603
Blood creatinine increased 74.21 37.34 47 4244 26853 4607848
Paranoia 73.80 37.34 27 4264 4562 4630139
Hypophagia 73.15 37.34 31 4260 7717 4626984
Crying 72.52 37.34 29 4262 6234 4628467
Aphasia 72.29 37.34 32 4259 8848 4625853
Memory impairment 70.01 37.34 41 4250 20362 4614339
Psychotic disorder 69.36 37.34 33 4258 10762 4623939
Hepatitis 68.46 37.34 34 4257 12171 4622530
Hypertension 67.42 37.34 57 4234 50741 4583960
Toxicity to various agents 66.62 37.34 66 4225 71974 4562727
Orthostatic hypotension 66.54 37.34 28 4263 6846 4627855
Extrapyramidal disorder 66.44 37.34 26 4265 5280 4629421
Blood urea increased 66.33 37.34 30 4261 8720 4625981
Bundle branch block left 66.03 37.34 20 4271 1884 4632817
Acute kidney injury 66.01 37.34 65 4226 70366 4564335
Blood pressure increased 65.53 37.34 45 4246 29415 4605286
Oedema peripheral 63.86 37.34 51 4240 41921 4592780
Failure to thrive 63.12 37.34 20 4271 2187 4632514
Renal failure 62.36 37.34 50 4241 41319 4593382
Insomnia 60.40 37.34 51 4240 45294 4589407
Dyspnoea 59.62 37.34 86 4205 138899 4495802
Blood sodium increased 59.46 37.34 16 4275 985 4633716
Cardiac failure 59.08 37.34 41 4250 27247 4607454
Atrial fibrillation 58.60 37.34 43 4248 31172 4603529
Apathy 58.06 37.34 20 4271 2835 4631866
Blood alkaline phosphatase increased 56.16 37.34 30 4261 12477 4622224
Delusion 55.64 37.34 22 4269 4588 4630113
Muscular weakness 55.39 37.34 39 4252 26511 4608190
Muscle rigidity 55.12 37.34 21 4270 3966 4630735
Dysphagia 54.42 37.34 38 4253 25493 4609208
Depression 54.14 37.34 49 4242 47684 4587017
Haemoglobin decreased 53.55 37.34 44 4247 37613 4597088
Hypotonia 53.29 37.34 20 4271 3626 4631075
Haematocrit decreased 53.28 37.34 26 4265 8956 4625745
Aspartate aminotransferase increased 52.88 37.34 37 4254 24901 4609800
Mania 50.28 37.34 21 4270 5037 4629664
Electrocardiogram PR prolongation 50.13 37.34 11 4280 284 4634417
Hypersomnia 49.96 37.34 20 4271 4307 4630394
Cerebrovascular accident 49.37 37.34 44 4247 41956 4592745
Ataxia 49.04 37.34 21 4270 5356 4629345
Headache 48.50 37.34 73 4218 122300 4512401
Bradyarrhythmia 48.31 37.34 13 4278 800 4633901
Death 48.02 37.34 95 4196 198068 4436633
Electroencephalogram abnormal 48.01 37.34 15 4276 1566 4633135
Unresponsive to stimuli 47.54 37.34 25 4266 10068 4624633
Pancreatitis 47.31 37.34 30 4261 17148 4617553
Loss of personal independence in daily activities 46.69 37.34 23 4268 8082 4626619
Pleural effusion 46.66 37.34 34 4257 24364 4610337
Alanine aminotransferase increased 46.40 37.34 36 4255 28337 4606364
Irritability 46.32 37.34 27 4264 13272 4621429
Blood albumin decreased 46.26 37.34 18 4273 3596 4631105
Incoherent 45.85 37.34 15 4276 1815 4632886
Eating disorder 45.76 37.34 18 4273 3702 4630999
Pneumonia aspiration 45.60 37.34 24 4267 9682 4625019
White blood cell count increased 45.41 37.34 28 4263 15239 4619462
Rash 44.85 37.34 66 4225 108322 4526379
Mental impairment 44.62 37.34 19 4272 4779 4629922
Hypernatraemia 44.00 37.34 15 4276 2060 4632641
Metastases to central nervous system 43.96 37.34 18 4273 4106 4630595
Cardiac failure congestive 43.75 37.34 37 4254 32885 4601816
Blood pressure decreased 43.74 37.34 29 4262 17871 4616830
Vertigo 43.39 37.34 27 4264 14929 4619772
Behaviour disorder 43.36 37.34 10 4281 325 4634376
Blood pressure systolic increased 43.20 37.34 18 4273 4290 4630411
Blood creatine phosphokinase increased 43.16 37.34 27 4264 15072 4619629
Akathisia 43.08 37.34 17 4274 3526 4631175
Jaundice 42.59 37.34 25 4266 12449 4622252
Musculoskeletal stiffness 42.30 37.34 29 4262 18873 4615828
Blood sodium decreased 41.41 37.34 19 4272 5703 4628998
Hip fracture 41.35 37.34 20 4271 6754 4627947
Hypoglycaemia 40.62 37.34 28 4263 18381 4616320
Subdural haematoma 39.99 37.34 19 4272 6167 4628534
Conduction disorder 39.22 37.34 11 4280 790 4633911
Deep vein thrombosis 38.78 37.34 31 4260 25463 4609238
Feeling abnormal 38.58 37.34 36 4255 36369 4598332
Diet refusal 38.52 37.34 9 4282 310 4634391
Heart rate increased 38.10 37.34 27 4264 18515 4616186
Cerebral ischaemia 37.55 37.34 14 4277 2490 4632211
Nightmare 37.53 37.34 19 4272 7071 4627630
Completed suicide 37.53 37.34 38 4253 42407 4592294

Pharmacologic Action:

SourceCodeDescription
ATC N06DA52 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DA53 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DX01 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Other anti-dementia drugs
FDA MoA N0000020015 NMDA Receptor Antagonists
FDA EPC N0000175745 N-methyl-D-aspartate Receptor Antagonist
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:35469 antidepressant
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018691 Excitatory Amino Acid Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Moderate to Severe Alzheimer's Type Dementia indication
Acute nephropathy contraindication 58574008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
14MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMENDA XR FOREST LABS LLC N022525 June 21, 2010 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate NMDA receptor; GRIN1/GRIN2B Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.26 CHEMBL CHEMBL
Glutamate receptor ionotropic, NMDA 3A Ion channel NEGATIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Glutamate NMDA receptor; GRIN1/GRIN2A Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 9.02 CHEMBL CHEMBL
Glutamate receptor ionotropic, NMDA 1 Ion channel NEGATIVE ALLOSTERIC MODULATOR IC50 5.02 CHEMBL CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
5-hydroxytryptamine receptor 3A Ion channel WOMBAT-PK
Glutamate receptor ionotropic, NMDA 2C Ion channel Ki 6.15 CHEMBL

External reference:

IDSource
4021409 VUID
N0000148824 NUI
C0025242 UMLSCUI
D04905 KEGG_DRUG
406457005 SNOMEDCT_US
6719 RXNORM
406458000 SNOMEDCT_US
4021409 VANDF
d04899 MMSL
006597 NDDF
4054 PUBCHEM_CID
CHEBI:64312 CHEBI
CHEMBL807 ChEMBL_ID
DB01043 DRUGBANK_ID
CHEMBL1699 ChEMBL_ID
JY0WD0UA60 UNII
41100-52-1 SECONDARY_CAS_RN
377 PDB_CHEM_ID
3952 INN_ID
D008559 MESH_DESCRIPTOR_UI
4253 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0121-0850 SOLUTION 10 mg ORAL ANDA 19 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-5435 CAPSULE, EXTENDED RELEASE 7 mg ORAL ANDA 17 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-5436 CAPSULE, EXTENDED RELEASE 14 mg ORAL ANDA 17 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-5437 CAPSULE, EXTENDED RELEASE 21 mg ORAL ANDA 17 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-5438 CAPSULE, EXTENDED RELEASE 28 mg ORAL ANDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1207 CAPSULE 7 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1214 CAPSULE 14 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1221 CAPSULE 21 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1228 CAPSULE 28 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 8 0456-1229 KIT 14 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 8 0456-1229 KIT 21 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 8 0456-1229 KIT 7 mg ORAL NDA 17 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 8 0456-1229 KIT 28 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 2 0456-3200 KIT 5 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 2 0456-3200 KIT 10 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3202 SOLUTION 2 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3205 TABLET 5 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3210 TABLET 10 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 4 0456-3400 KIT 28 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 4 0456-3400 KIT 7 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 4 0456-3400 KIT 21 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 4 0456-3400 KIT 14 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3407 CAPSULE, EXTENDED RELEASE 7 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3414 CAPSULE, EXTENDED RELEASE 14 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3421 CAPSULE, EXTENDED RELEASE 21 mg ORAL NDA 17 sections
Namenda HUMAN PRESCRIPTION DRUG LABEL 1 0456-3428 CAPSULE, EXTENDED RELEASE 28 mg ORAL NDA 17 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1221 TABLET 5 mg ORAL ANDA 17 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1222 TABLET 10 mg ORAL ANDA 17 sections
Memantine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1943 SOLUTION 2 mg ORAL ANDA 19 sections
memantine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3870 TABLET 5 mg ORAL NDA 17 sections